Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Conmed | HOLD | ― | -7.00% | Downgraded | Conmed falls as Needham downgrades to holdNeedham has downgraded Conmed ( NYSE: ) to hold from buy citing a decline in its long-term growth rate. | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $135 | ― | 19.00% | Reiterated | ||||
 | Enliven Therapeutics | BUY $38→$37 | ― | -5.20% | Reiterated | Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 6.20% | Upgraded | ||||
 | Air Products and Chemicals | BUY $355 | ― | -5.10% | Initiated | Air Products initiated with an Outperform at RBC Capital | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $760 | ― | 11.40% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $165→$210 | ― | 9.60% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $6→$7 | ― | 1.00% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $69 | ― | 13.30% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $240 | ― | 11.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $213 | ― | 2.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $240 | ― | 11.00% | Reiterated | ||||
 | Kenvue, Inc. | HOLD $24.5 | ― | -1.80% | Reiterated | Kenvue, Inc.'s Strategic Moves and Market Position: Hold Rating Amid Limited Divestiture Plans | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $41 | ― | 25.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $260→$385 | ― | 16.30% | Upgraded | ||||
| Intellia Therapeutics | BUY $50 | ― | -6.10% | Reiterated | Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating | |||
| Nurix Therapeutics | BUY $35 | ― | -0.30% | Reiterated | Promising Developments in Nurix Therapeutics' BTK Degrader Drive Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $70 | ― | 4.40% | Reiterated | ||||
| Establishment Labs Holdings | BUY $62 | ― | -8.40% | Reiterated | Establishment Labs Holdings: Strong Growth Potential and Strategic Initiatives Drive Buy Rating | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $67→$80 | ― | 1.40% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $60→$50 | ― | 1.40% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $43 | ― | 1.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $32→$40 | ― | 1.40% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $10→$9 | ― | 1.40% | Downgraded | ||||
 | USA Rare Earth | BUY $17 | ― | -1.00% | Initiated | USA Rare Earth initiated with a Buy at Canaccord | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $77 | ― | 13.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $475 | ― | 3.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $80 | ― | 6.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $48→$47 | ― | 1.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $39→$42 | ― | 1.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $33→$35 | ― | 1.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $185 | ― | 48.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 15.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $430→$470 | ― | 1.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250→$275 | ― | 9.80% | Reiterated | ||||
 | Monster Beverage | BUY $67→$70 | ― | 0.10% | Reiterated | Monster Beverage (MNST) Receives a Buy from Wells Fargo | |||
| Fortrea Holdings Inc. | SELL $5 | ― | -9.50% | Reiterated | Barclays Sticks to Its Sell Rating for Fortrea Holdings Inc. (FTRE) | |||
 | Expand Energy | BUY $130→$135 | ― | -8.70% | Reiterated | Analysts Offer Insights on Energy Companies: Kinder Morgan (NYSE: KMI) and Expand Energy (NASDAQ: EXE) | |||
 | RH | BUY $436 | ― | -7.30% | Reiterated | RH (RH) Receives a Buy from Barclays | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $31 | ― | 16.60% | Reiterated | ||||
 | Nurix Therapeutics | BUY $31 | ― | -7.80% | Reiterated | Barclays Remains a Buy on Nurix Therapeutics (NRIX) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $91 | ― | 16.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $990 | ― | 16.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $72 | ― | 7.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 11.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $84 | ― | 16.30% | Reiterated | ||||
| Blueprint Medicines | HOLD $105→$129 | ― | -7.80% | Reiterated | Barclays Sticks to Their Hold Rating for Blueprint Medicines (BPMC) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $128 | ― | 9.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $235 | ― | 4.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $567 | ― | 17.00% | Reiterated |
Rows:
